エクスポート完了 — 

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

Most melanomas harbor oncogenic BRAF(V600) mutations, which constitutively activate the MAP kinase (MAPK) pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF(V600)-mutant melanoma, it remains incompletely understood why 10-20% of patients fail to respond. Here, we show that RAF i...

詳細記述

保存先:
書誌詳細
主要な著者: Konieczkowski, David J., Johannessen, Cory M., Abudayyeh, Omar, Kim, Jong Wook, Cooper, Zachary A., Piris, Adriano, Frederick, Dennie T., Barzily-Rokni, Michal, Straussman, Ravid, Haq, Rizwan, Fisher, David E., Mesirov, Jill P., Hahn, William C., Flaherty, Keith T., Wargo, Jennifer A., Tamayo, Pablo, Garraway, Levi A.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154497/
https://ncbi.nlm.nih.gov/pubmed/24771846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0424
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料